EQT to acquire Qiagen at €46.50 per share in cash

The all-cash structure and the absence of disclosed financing or break-fee terms are the notable gaps here; the announcement confirms price and little else. A take-private of a diagnostics and life-sciences tools name matters less for crypto/RWA readers directly than as a signal of private capital's appetite for healthcare assets, which could influence how tokenized real-world asset platforms think about healthcare-linked collateral and data. The open question is whether the deal clears closing conditions without a competing bid or regulatory friction, and what the eventual leverage profile looks like once terms surface.